Incorporating New Prevention and Treatment Strategies Into HIV Care

Review the latest data on FTC/TAF as PrEP and extended-release injectable CAB plus RPV for long-acting treatment of patients with HIV.
W. David Hardy, MD
Anne-Geneviève Marcelin, PharmD, PhD
Kenneth Mayer, MD
Jürgen K. Rockstroh, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 529 KB
Released: January 28, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
ViiV Healthcare

Related Content

Dr Milena Murray and Clinical Care Options (CCO): Current pharmacokinetic and safety data support the use of tenofovir alafenamide during pregnancy

person default Milena Murray, PharmD, MSc, BCIDP, AAHIVP Released: September 15, 2021

Download CCO slides reviewing clinically relevant new data reported at IAS 2021 on a wide range of ART management topics.

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Daniel R. Kuritzkes, MD
Released: September 13, 2021

Dr Jason Halperin and Clinical Care Options (CCO): Rapid ART in adolescents leads to virologic suppression and upholds equity

Jason Halperin, MD, MPH Released: September 10, 2021

Dr Jason Halperin and Clinical Care Options (CCO): Medication treatment for OUD improves HIV viral suppression rates

Jason Halperin, MD, MPH Released: September 10, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue